Wolverine Stack: BPC-157 and TB-500 Research Guide

Research guide · Updated October 2026 · 12 minute read

The Wolverine Stack is the research community’s name for BPC-157 and TB-500 supplied together as one blend. Over 8,000 people a month search for the “Wolverine peptide stack,” and more than 22,000 search for BPC-157 and TB-500 together. Most of what they find is opinion. This guide sticks to the published record.

Both peptides come out of three decades of preclinical tissue research. They are studied side by side because they act on separate parts of the repair process in cell and animal models: BPC-157 on blood supply and signaling, TB-500 on cell movement.

Below you will find what each compound is, how BPC-157 and TB-500 compare, the pathways each has been studied for, what the evidence does and does not show, half life data, and where both stand with the FDA and WADA as of October 2026. Every factual claim links to its source in the references.

For in vitro and laboratory research only. Nothing on this page is medical advice, and no dosing or administration guidance is provided.

Contents

1. What is the Wolverine Stack?
2. BPC-157 at a glance
3. TB-500 and thymosin beta 4
4. BPC-157 vs TB-500
5. Why researchers study BPC-157 and TB-500 together
6. What the research shows, and its limits
7. BPC-157 and TB-500 half life
8. Research timeline
9. Regulatory status in 2026
10. Storage and handling in the lab
11. How to check research peptide quality
12. The Peptidist Wolverine Stack
13. Frequently asked questions
14. References

What is the Wolverine Stack?

“Wolverine Stack” is an informal name, borrowed from the comic book character known for rapid regeneration. In research supply it means a combination of two synthetic peptides:

• BPC-157, a 15 amino acid fragment of a protein first described in human gastric juice [1]
• TB-500, synthetic material based on thymosin beta 4 (Tβ4), a 43 amino acid peptide found in nearly every human cell type [7]

The term appears across research supplier catalogs, forums and Reddit threads. It does not appear in the scientific literature, which studies each compound on its own. Neither compound is an approved drug, and both are sold in the United States as research chemicals for laboratory use.

BPC-157 at a glance

Full name	Body Protection Compound 157
Type	Synthetic pentadecapeptide
Sequence	Gly Glu Pro Pro Pro Gly Lys Pro Ala Asp Asp Ala Gly Leu Val (GEPPPGKPADDAGLV)
Amino acids	15
Molecular weight	1,419.5 g/mol
CAS number	137525-51-0
Origin	Partial sequence of a protein isolated from human gastric juice

Predrag Sikirić’s group at the University of Zagreb introduced BPC and its 15 amino acid fragment in 1993 [1], and that group still produces most of the BPC-157 literature. The peptide’s stability in gastric acid set it apart from most peptides and made it a frequent subject in gut research.

In rodent and cell culture studies, BPC-157 has been examined in tendon, ligament, muscle, vascular and gastrointestinal tissue. Mechanistic work points to three pathways:

• VEGFR2 signaling. In a 2017 study, BPC-157 increased vessel formation in chick embryo and endothelial cell assays and increased expression of VEGFR2, the main receptor for vascular growth signals [2].
• The nitric oxide system. The same study traced activation through the Akt and eNOS pathway, which produces nitric oxide and regulates blood vessel tone [2].
• FAK and paxillin in tendon fibroblasts. Rat tendon cells exposed to BPC-157 showed more outgrowth, survival under oxidative stress and migration, with higher FAK and paxillin activation [3]. A follow up study found increased growth hormone receptor expression in the same cell type [4].

TB-500 and thymosin beta 4

Parent peptide	Thymosin beta 4 (Tβ4)
Parent length	43 amino acids, molecular weight about 4,963 Da
Parent CAS number	77591-33-4
Fragment form	Ac-LKKTETQ, residues 17 to 23 of Tβ4
Key region	LKKTET, the actin binding motif
Natural sources	Thymus tissue, platelets, and nearly all nucleated cells

The name TB-500 covers two different materials. Some suppliers sell full length synthetic thymosin beta 4. Others sell the acetylated seven amino acid fragment that carries its actin binding region. The molecular weight on a certificate of analysis tells you which one a vial contains: about 4,963 Da for the full peptide, under 1,000 Da for the fragment.

Thymosin beta 4 binds actin monomers one to one and blocks them from polymerizing [8]. Actin is the structural protein that lets a cell change shape and move, so Tβ4 research centers on cell migration. Published animal work covers:

• Skin wounds. In a rat full thickness wound model, Tβ4 increased reepithelialization by 42% at day 4 and up to 61% at day 7, with more collagen deposition and new vessel growth [5].
• Heart tissue. A 2004 study in Nature found Tβ4 promoted migration and survival of heart cells in culture and improved cardiac function in mice after coronary ligation [6].
• Eye and nerve tissue. Reviewed alongside anti inflammatory and anti fibrotic activity in a 2012 overview [7].

BPC-157 vs TB-500

The two compounds differ in almost every respect that matters to a lab:

• Size. BPC-157 has 15 amino acids. Full Tβ4 has 43, nearly three and a half times the molecular weight.
• Origin. BPC-157 derives from a gastric protein. Tβ4 occurs naturally throughout the body, at high levels in platelets.
• Research focus. BPC-157 work centers on angiogenesis and signaling. Tβ4 work centers on actin and cell migration.
• Human data. BPC-157 has one retrospective clinical report in the orthopedic literature [9]. Tβ4 went through formal Phase 1 and Phase 2 trials as a drug candidate [10] [11].

Why researchers study BPC-157 and TB-500 together

The pairing rests on two mechanisms that do not overlap. BPC-157 research centers on blood supply and signaling: angiogenesis, nitric oxide and growth factor pathways. Thymosin beta 4 research centers on cell movement: actin regulation, which governs how cells reach and populate damaged tissue.

Because the pathways are distinct, one model can examine both at once. A point that most Wolverine Stack articles leave out: no published controlled study has tested BPC-157 and TB-500 in combination. The rationale for the stack is assembled from each compound’s separate literature.

What the research shows, and its limits

Search results for “TB-500 benefits” and “BPC-157 benefits” are full of confident claims. The published record is narrower.

What the evidence supports

• A large body of rodent and cell culture work on each compound, spanning tendon, skin, vascular, cardiac and gut models [2] [3] [5] [6].
• Defined mechanisms in those models: VEGFR2 and nitric oxide signaling for BPC-157, actin binding for Tβ4.
• For Tβ4 only, controlled human safety data. A Phase 1 study of intravenous Tβ4 in 40 healthy volunteers reported no dose limiting toxicity [10]. A Phase 2 trial of a topical Tβ4 gel in 73 patients with venous ulcers found safety comparable to placebo [11].

What it does not support

• Human efficacy for BPC-157. A 2025 systematic review found 36 studies on BPC-157 in orthopedic sports medicine. Thirty five were preclinical. The single clinical study was a retrospective report of 12 patients, and the authors state there is no clinical safety data in humans [9].
• Independent replication. Much of the BPC-157 literature comes from one research group.
• Short trials. In its 2026 review for the Pharmacy Compounding Advisory Committee, FDA staff found the five human BPC-157 trials available too short and too small to establish safety or effectiveness [13].
• The combination. No study has tested the two together.
• Long term safety data for either compound in humans.

Treat claims that go beyond animal and cell data with caution, including claims made by suppliers.

BPC-157 and TB-500 half life

BPC-157. The first pharmacokinetic study of BPC-157, published in 2022, measured an elimination half life of under 30 minutes for the intact peptide in both rats and dogs. It was cleared through urine and bile and broken down quickly into smaller fragments and amino acids [12].

TB-500. No pharmacokinetic study of TB-500 as sold has been published. The closest data comes from the Phase 1 trial of synthetic Tβ4, which reported dose proportional pharmacokinetics with a half life that increased at higher doses [10]. That trial used full length Tβ4, so its figures do not transfer to the seven amino acid fragment.

Research timeline

• 1991: Thymosin beta 4 identified as an actin sequestering peptide in human platelets [8].
• 1993: BPC and its fragment BPC-157 introduced by the Zagreb group [1].
• 1999: Tβ4 accelerates wound closure in rats [5].
• 2004: Tβ4 and cardiac cell migration published in Nature [6].
• 2010: First human trials of Tβ4 published: an IV safety study and a topical wound study [10] [11].
• 2011: BPC-157 shown to drive tendon fibroblast outgrowth and migration [3].
• 2017: BPC-157 linked to VEGFR2 activation [2].
• 2022: First BPC-157 pharmacokinetic study published [12].
• 2025: Systematic review finds 35 of 36 BPC-157 orthopedic studies are preclinical [9].
• 2026: FDA moves to remove both from its Category 2 list in April. An FDA advisory committee votes to recommend both for compounding in July [13] [14].

Regulatory status in 2026

FDA. Neither BPC-157 nor TB-500 is FDA approved. Both spent several years on the FDA’s Category 2 list of bulk substances that raise significant safety concerns for compounding [15]. On April 15, 2026 the FDA announced its intent to remove 12 peptides from Category 2, these two among them [14]. On July 23, 2026, the Pharmacy Compounding Advisory Committee voted 8 to 6, with one abstention, to recommend BPC-157, TB-500 and KPV for the 503A bulks list [13]. That vote is not binding. Compounding pharmacies can only use these substances after the FDA completes notice and comment rulemaking.

Sport. Both compounds are on the World Anti-Doping Agency Prohibited List and are banned at all times, in and out of competition. Athletes in tested sports have been sanctioned for both [16].

Research supply. Both are sold in the United States for in vitro and laboratory research. They are not for human or veterinary use.

Storage and handling in the lab

• Store lyophilized (freeze dried) peptide frozen at minus 20°C for long term stability, and refrigerate it on arrival for short term storage.
• Keep vials sealed and protected from light and moisture until use.
• Once reconstituted, keep material refrigerated and follow your laboratory’s own protocols for preparation, stability and disposal.
• Check the certificate of analysis for identity, purity and molecular weight before use.

How to check research peptide quality

The research peptide market has no pharmaceutical oversight, so the certificate of analysis is the main safeguard. A useful one shows:

• The testing lab’s name. Independent third party labs carry more weight than in house testing.
• HPLC purity as a percentage of peak area, with the chromatogram itself.
• Mass spectrometry confirming molecular weight. For TB-500 this is the only way to tell the full peptide from the fragment.
• A date recent enough to reflect the material you receive.

The Peptidist Wolverine Stack

Peptidist supplies the Wolverine Stack 10mg as a two peptide research blend, plus a liquid format in the Wolverine Nasal Spray. For single compound work, BPC-157 5mg is available on its own.

• Every batch is independently tested by Chromate using HPLC, with the certificate of analysis on the product page.
• Orders placed before 3:00 PM ET on business days ship the same day by FedEx Express.
• Free shipping on orders over $500, and every order includes free shipment protection.
• Buy 2 Get 1 Free applies sitewide.

View the Wolverine Stack

Frequently asked questions

What is in the Wolverine Stack?

BPC-157 and TB-500, two synthetic peptides supplied together as one research blend.

Why is it called the Wolverine Stack?

The name comes from the comic book character known for regeneration. It reflects the tissue repair focus of the preclinical research on both compounds.

What is the difference between BPC-157 and TB-500?

BPC-157 is a 15 amino acid fragment of a gastric protein, studied mainly for angiogenesis and growth factor signaling. TB-500 is based on thymosin beta 4, a 43 amino acid peptide studied for actin binding and cell migration.

Is TB-500 the same as thymosin beta 4?

Not always. TB-500 is sold either as full length synthetic thymosin beta 4 (43 amino acids) or as its seven amino acid fragment Ac-LKKTETQ. The molecular weight on the certificate of analysis shows which one you have.

What is the half life of BPC-157?

Under 30 minutes for the intact peptide in rats and dogs, according to the only published pharmacokinetic study. No human half life data exists.

Has the combination been studied?

Each peptide has an extensive preclinical literature on its own. No published controlled study has tested the two together.

Is the Wolverine Stack FDA approved?

No. Neither BPC-157 nor TB-500 is FDA approved. An FDA advisory committee recommended both for the 503A compounding list in July 2026, but that recommendation is not binding and requires rulemaking before it takes effect.

Are BPC-157 and TB-500 banned in sport?

Yes. Both are on the WADA Prohibited List and are banned in and out of competition.

Do you provide dosing information?

No. Peptidist supplies research material only. Preparation and handling follow your own laboratory protocols.

References

1. Sikirić P, et al. A new gastric juice peptide, BPC. An overview of the stomach stress organoprotection hypothesis and beneficial effects of BPC. J Physiol Paris. 1993;87(5):313-27. PubMed 8298609
2. Hsieh MJ, et al. Therapeutic potential of pro angiogenic BPC157 is associated with VEGFR2 activation and up regulation. J Mol Med (Berl). 2017;95(3):323-33. PubMed 27847966
3. Chang CH, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011;110(3):774-80. PubMed 21030672
4. Chang CH, et al. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014;19(11):19066-77. PubMed 25415472
5. Malinda KM, et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999;113(3):364-8. PubMed 10469335
6. Bock-Marquette I, et al. Thymosin beta4 activates integrin linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004;432(7016):466-72. PubMed 15565145
7. Goldstein AL, et al. Thymosin β4: a multi functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012;12(1):37-51. PubMed 22074294
8. Safer D, et al. Thymosin beta 4 and Fx, an actin sequestering peptide, are indistinguishable. J Biol Chem. 1991;266(7):4029-32. PubMed 1999398
9. Vasireddi N, et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS J. 2025;21(4):485-95. PubMed 40756949
10. Ruff D, et al. A randomized, placebo controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers. Ann N Y Acad Sci. 2010;1194:223-9. PubMed 20536472
11. Guarnera G, et al. The effect of thymosin treatment of venous ulcers. Ann N Y Acad Sci. 2010;1194:207-12. PubMed 20536470
12. He L, et al. Pharmacokinetics, distribution, metabolism, and excretion of body protective compound 157 in rats and dogs. Front Pharmacol. 2022;13:1026182. PubMed 36588717
13. AJMC. FDA panel backs 6 peptides for compounding. July 2026. ajmc.com
14. Goodwin Procter. FDA signals potentially evolving stance toward compounding of certain peptides. May 2026. goodwinlaw.com
15. U.S. Food and Drug Administration. Safety risks associated with certain bulk drug substances nominated for use in compounding. fda.gov
16. BSCG. TB-500 status, risks and bans in sport and the military. bscg.org

For in vitro and laboratory research only. Not for human or veterinary use. Statements on this page describe published preclinical research and have not been evaluated by the Food and Drug Administration.